847925-91-1 | RO4929097

Packsize	Purity	Availability	Price	Discounted Price
1mg	98+%	in stock	$29.00	$20.00
5mg	98+%	in stock	$69.00	$49.00
25mg	98%	in stock	$255.00	$178.00
100mg	98%	in stock	$706.00	$494.00

Description

• Catalog Number: AB53170
• Chemical Name: RO4929097
• CAS Number: 847925-91-1
• Molecular Formula: C22H20F5N3O3
• Molecular Weight: 469.4045
• MDL Number: MFCD18384976
• SMILES: O=C1Nc2ccccc2c2c([C@@H]1NC(=O)C(C(=O)NCC(C(F)(F)F)(F)F)(C)C)cccc2

Computed Properties

• Complexity: 771
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 5
• XLogP3: 4.6

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120701

• Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.

  Pediatric blood & cancer 20120501

• A phase II study of RO4929097 in metastatic colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20120501

• High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.

  Molecular oncology 20110601

• Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110601

• The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.

  PloS one 20110101

• Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

  Cancer research 20091001